- Home
- THFF vs KROS Comparison
THFF vs KROS Comparison
Compare THFF & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THFF | KROS |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.4M | 584.9M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | THFF | KROS |
|---|---|---|
| Price | $60.02 | $10.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $62.00 | $22.25 |
| AVG Volume (30 Days) | 53.3K | ★ 415.8K |
| Earning Date | 04-21-2026 | 03-04-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | 67.00 | ★ 146.00 |
| EPS | ★ 6.68 | 2.30 |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | $17.86 | N/A |
| Revenue Next Year | $3.55 | $727.07 |
| P/E Ratio | $9.13 | ★ $4.83 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.05 | $9.12 |
| 52 Week High | $69.21 | $22.55 |
Technical Indicators
Market Signals| Indicator | THFF | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 22.11 |
| Support Level | $59.02 | $10.49 |
| Resistance Level | $60.77 | $15.21 |
| Average True Range (ATR) | 1.53 | 0.66 |
| MACD | -0.28 | 0.03 |
| Stochastic Oscillator | 3.88 | 6.56 |
Price Performance
Historical ComparisonAbout THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.